文献速递免疫规划卫生政策与健康促进

B群脑膜炎球菌疫苗经济学评价:系统综述

Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
PubMed 文献 · Vaccine · 2021-03-18

本系统综述纳入13项研究,评估MenB疫苗接种的成本效果。纳入群体效应可改善经济性,婴儿常规接种短期最有效,青少年策略性价比最优。常规MenB接种因疫苗成本高、发病率低,不具显著经济价值。

要点

  • 所有MenB疫苗接种策略均未被判定为具成本效果。
  • 纳入群体效应可改善MenB疫苗的成本效果。
  • 婴儿常规接种短期最有效,青少年策略性价比最优。

核心结论

  • 常规MenB疫苗接种不具显著经济价值,主要因疫苗成本高且疾病发病率低。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、Web of Science、NHS EED、Econlit、Tufts CEA registry和HTA,由三名评价员独立筛选,采用叙述性综合按接种策略分类,并用CHEERS清单评估质量。

主要发现

  • 所有疫苗接种策略均未被判定为具成本效果。
  • 纳入群体效应可改善MenB疫苗的成本效果。
  • 婴儿常规接种是短期最有效策略,但青少年策略性价比最优。
  • 无群体免疫时,婴儿常规接种的增量成本效果比估计值最低。

临床怎么用

  • 决策者可参考本综述,在评估MenB疫苗引入时需考虑高成本与低发病率对经济性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningococcal serogroup B (MenB) has emerged as the leading cause of invasive meningococcal disease (IMD) in several countries following the release of effective vaccines against serogroups A, C, W, and Y. In 2013, however, the first multicomponent MenB vaccine (Bexsero®) was licensed in Europe. AIM: To review the evidence on the cost-effectiveness of vaccination against MenB. METHODS: Searches were performed in MEDLINE, EMBASE, Web of Science, NHS EED, Econlit, Tufts CEA registry, and HTA. Three reviewers independently screened and selected studies. Using a narrative synthesis, studies were categorized by vaccination strategies. The quality of included studies was assessed using the Comparative Health Economics Evaluation Reporting Standards (CHEERS) checklist. RESULTS: 13 studies were included. Ten studies were conducted in the European region and three in the Americas. None of the vaccination strategies were considered cost-effective. Including herd effects improved value for money for MenB vaccines. Routine infant vaccination was the most effective short-term strategy, however, adolescent strategies offered the best value for money. Without herd immunity, routine infant vaccination had the lowest incremental cost-effectiveness ratio estimates. CONCLUSION: Routine MenB vaccination does not offer substantial value for money, mainly due to high vaccine costs and low disease incidence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nwogu IB, Jones M, Langley T, et al. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review. Vaccine. 2021. PMID: 33744052. doi:10.1016/j.vaccine.2021.02.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。